All In Biotech

Drug Trial Radar · NCT03608020

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

A Safety Lead-In/Randomized Phase 2 Study of BMX-001 as a Therapeutic Agent for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Last checked: Nov 19, 2026Latest source record: Apr 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

35

Actual

Start

Oct 4, 2018

Primary completion

Dec 31, 2023

Study completion Apr 15, 2024

Sponsor

Lead sponsor
BioMimetix JV, LLCIndustry
Sponsor type
Industry
Collaborators
Duke Cancer Institute; National Cancer Institute (NCI)
First posted
Jul 31, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol is for a lead-in safety study of 5 patients followed by a randomized Phase 2 clinical trial of BMX-001, a new class of pharmaceutical, in 64 patients with multiple brain metastases (MBM) undergoing whole brain radiation therapy (WBRT). Preliminary studies have demonstrated that BMX-001 provides protection of normal tissues from radiation-induced injury and augments tumor growth inhibition.

Conditions

  • Multiple Brain Metastases

Interventions

  • BMX-001Drug

    Manganese butoxyethyl pyridyl porphyrin

  • Whole Brain Radiation TherapyRadiation

    Whole Brain Radiation Therapy per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess safety and tolerability of WBRT + BMX-001 through proportion of patients who experience grade 4 or 5 study drug related adverse events.Time frame: 1 year
  2. Compare neurocognition in WBRT + BMX-001 vs. WBRT alone using cumulative score of HVLT-R, TMT A&B and COWA over time.Time frame: 1 Year

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kentucky

    Lexington, Kentucky

  • Henry Ford Hospital

    Detroit, Michigan

  • Duke Cancer Institute

    Durham, North Carolina

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.